Luca Guarnera, MD, Cleveland Clinic, Cleveland, OH & University of Rome "Tor Vergata", Rome, Italy, discusses long-term outcomes of ATRO-ATO (all-trans retinoic acid – arsenic trioxide) treatment for patients with newly diagnosed acute promyelocytic leukemia (APL), an aggressive subtype of acute myeloid leukemia (AML), based on data from the HARMONY platform. The analysis indicates that high-risk patients will benefit from this chemotherapy-free regimen. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
